HO-1核转位调控NPM1/MDM2/p53/Arf:非酶活性依赖的血管内皮应激性衰老调节新机制
批准号:
81973318
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
李卓明
依托单位:
学科分类:
心脑血管药物药理
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
李卓明
中文摘要
血红素加氧酶-1(HO-1)作为机体最重要的氧化应激防御酶而备受关注,但其非酶活性功能目前所知甚少,对心血管系统的调控作用尚不清楚。在血管内皮应激性衰老模型中,我们发现:HO-1出现明显核聚集;核内HO-1显著抑制内皮衰老,且该作用不依赖于酶活性;HO-1在核内通过与核仁磷酸蛋白NPM1相互作用,降低p53稳定性。据此我们提出假设:在内皮应激性衰老中,HO-1转位入核与NPM1结合,通过干扰胞核中NPM1/MDM2/p53/Arf相互作用,抑制p53、Arf等细胞周期抑制因子,发挥阻抑内皮衰老的保护作用。本项目拟采用基因工程小鼠、Crispr Cas9基因编辑等体内外实验手段,探究HO-1核转位在内皮衰老和血管稳态调节中的关键作用及调控机制,揭示HO-1抗氧化作用以外的新功能,以及其与酶依赖性内皮保护的协同作用及机制,为确立以HO-1为靶标干预血管老化、防治心血管疾病提供更充分的科学依据。
英文摘要
Heme oxygenase-1 (HO-1) serves as the most important endogenous enzyme against oxidative stress, and has attracted lots of attention for its heme-degraded enzymatic activity. However, it remains unclear whether HO-1 has non-enzymatic activity. And the exact regulatory role of its non-enzymatic activity in the cardiovascular system is under explored. In our previous observations, HO-1 was translocated into the nucleus in senescent vascular endothelial cells; nuclear HO-1 elicited anti-senescent effect independent of its enzymatic activity. Further observations demonstrated that nuclear HO-1 interacted with nucleophosmin (NPM1) to repress p53 stability. Based on these observations, a hypothesis was proposed: HO-1 translocated to the nucleus and interacted with NPM1 during endothelial senescence, interfering with NPM1/MDM2/p53/Arf interactions, inhibiting the cell-cycle repressors p53 and Arf, and subsequently protecting the endothelial cells against senescence. The present study will pave the way to illuminate the mechanisms underlying the regulation of nuclear HO-1 in endothelial senescence and vascular homeostasis, and will provide better understanding of the novel function of HO-1 besides its anti-oxidant effect, and the synergistic effect of its enzymatic and non-enzymatic activity in endothelial protection. This study will also provide solid evidence for HO-1 as a therapeutic strategy of vascular senescence and cardiovascular diseases.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
登录
查看更多内容
Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/β-catenin
Prmt5 引起的组蛋白 H4R3 对称二甲基化通过调节 Filip1L/β-catenin 防止心脏肥大
DOI:
10.1016/j.phrs.2020.105104
发表时间:
2020-11-01
期刊:
PHARMACOLOGICAL RESEARCH
影响因子:
9.3
作者:
[Cai, Sidong, Wang, Panxia, Liu, Peiqing]
通讯作者:
Liu, Peiqing
HO-1 nuclear accumulation and interaction with NPM1 protect against stress-induced endothelial senescence independent of its enzymatic activity.
HO-1 核积累以及与 NPM1 的相互作用可防止应激诱导的内皮衰老,与其酶活性无关
DOI:
10.1038/s41419-021-04035-6
发表时间:
2021-07-26
期刊:
Cell death & disease
影响因子:
9
作者:
[Luo W, Li J, Li Z, Lin T, Zhang L, Yang W, Mai Y, Liu R, Chen M, Dai C, Yang H, Lu J, Li H, Guan G, Huang M, Liu P, Li Z]
通讯作者:
Li Z
PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression.
PRMT5 通过对称二甲基化 HoxA9 和抑制 HoxA9 表达来防止心肌细胞肥大
DOI:
10.3389/fphar.2020.600627
发表时间:
2020
期刊:
Frontiers in pharmacology
影响因子:
5.6
作者:
[Cai S, Liu R, Wang P, Li J, Xie T, Wang M, Cao Y, Li Z, Liu P]
通讯作者:
Liu P
DOI:
10.1016/j.redox.2023.102652
发表时间:
2023-06
期刊:
REDOX BIOLOGY
影响因子:
11.4
作者:
[Wang, Minghui, Ding, Yanqing, Hu, Yuehuai, Li, Zeyu, Luo, Wenwei, Liu, Peiqing, Li, Zhuoming]
通讯作者:
Li, Zhuoming
PEX5 prevents cardiomyocyte hypertrophy via suppressing the redox-sensitive signaling pathways MAPKs and STAT3
PEX5 通过抑制氧化还原敏感信号通路 MAPK 和 STAT3 来防止心肌细胞肥大
DOI:
10.1016/j.ejphar.2021.174283
发表时间:
2021
期刊:
European Journal of Pharmacology
影响因子:
5
作者:
[Wang Minghui, Li Jingyan, Ding Yanqing, Cai Sidong, Li Zhuoming, Liu Peiqing]
通讯作者:
Liu Peiqing
共 11 条
基于线粒体-过氧化物酶体互作的SIRT3/PEX5调控病理性心肌肥大新机制
-
批准号:--
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:李卓明
-
依托单位:
基于PFKP-K736乙酰化修饰探讨靶向内皮细胞糖酵解代谢的血管内皮应激性衰老干预策略
-
批准号:82273925
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:李卓明
-
依托单位:
基于PFKP乙酰化修饰探讨衰老血管内皮细胞能量代谢紊乱的分子机制
-
批准号:--
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:李卓明
-
依托单位:
HO-1对血管内皮细胞应激性衰老的调控机制
-
批准号:81400359
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:李卓明
-
依托单位:
国内基金
海外基金